Miki Toshio
Department of Surgery, Keck School of Medicine, University of Southern California, Los Angeles, United States.
Gastroenterol Hepatol. 2019 Mar;42(3):202-208. doi: 10.1016/j.gastrohep.2018.10.007. Epub 2018 Nov 22.
A severe shortage of suitable allografts is a long-standing and worldwide problem for patients who are waiting for organ transplantation. Hepatocyte transplantation has been proposed as an alternative therapeutic approach for liver disease patients to address this urgent and unmet medical need. The cell replacement approach does not replace orthotopic liver transplantation (OLT), but rather it complements OLT especially for patients who do not require whole liver replacement, such as those with congenital metabolic disorders. This review article summarizes the current knowledge and limitations of clinical hepatocyte transplantation and aims to advance our understanding toward the goal of developing novel cell replacement therapies for patients who are on the OLT waiting list.
对于等待器官移植的患者而言,合适的同种异体移植物严重短缺是一个长期存在且全球范围内的问题。肝细胞移植已被提议作为肝病患者的一种替代治疗方法,以满足这一迫切且未得到满足的医疗需求。细胞替代方法并非取代原位肝移植(OLT),而是对OLT起到补充作用,特别是对于那些不需要全肝置换的患者,比如患有先天性代谢紊乱的患者。这篇综述文章总结了临床肝细胞移植的现有知识和局限性,旨在推动我们对于为OLT等待名单上的患者开发新型细胞替代疗法这一目标的理解。